Buy & Sell Amylx Pharmaceuticals Inc (AMLX) – Amylx Pharmaceuticals Inc Price Today
Aura AI Summary
Key Stats
- $1.58BMarket Cap
- HealthSector
- -30.61%3M Drawdown
- $1.30BEnterprise Value
- -Dividend Yield
- 84% Buy | 16% SellTrading Activity
- 7 daysTypical Hold Time
Amylx Pharmaceuticals Inc (AMLX) is currently valued at a market capitalization of $1.58B, with an enterprise value of $1.30B. Over the past 52 weeks, Amylx Pharmaceuticals Inc has traded between a low of $4.9 and a high of $18.36, highlighting its annual price range. Over the past three months, Amylx Pharmaceuticals Inc has recorded a drawdown of -30.61%, reflecting recent price volatility. On average, investors hold Amylx Pharmaceuticals Inc for approximately 7 days, indicating typical investor behavior on the platform.
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Most Recent News
Universal Music Group rejects Pershing Square's undervalued buyout proposal, confident in growth strategy.
Universal Music Group's Board of Directors unanimously rejected an unsolicited buyout proposal from Pershing Square Capital Management, stating it undervalues the company and won't create superior value. The Board, supported by shareholders, highligh...

JPMorgan's Dimon clashes with Coinbase CEO over crypto regulation and Clarity Act opposition.
JPMorgan CEO Jamie Dimon sharply criticized Coinbase CEO Brian Armstrong, calling him "full of s–t" amid a battle over crypto regulation in the U.S. Dimon opposes the current Clarity Act, which aims to regulate digital assets, arguing that crypto pla...

4% withdrawal rule risks vary with market timing; early losses can halve retirement savings.
A retiree with a $2.4 million portfolio following the 4% withdrawal rule faces significant sequence-of-returns risk. Early market downturns, like the 2000-2002 dot-com crash, can drastically reduce portfolio value despite average returns of 7%. Strat...
